10-Q: PURE Bioscience Reports Continued Losses and Going Concern Doubts Amidst Increased Related-Party Debt

PURE Bioscience, Inc. filed its quarterly report, revealing ongoing net losses and a significant stockholders' deficiency, raising substantial doubt about its ability to continue as a going concern, despite increased revenue in the recent quarter and new convertible note financing from related parties.

Summary

• PURE Bioscience, Inc. reported a net loss of $2,067,000 for the nine months ended April 30, 2025, an improvement from a $2,594,000 net loss in the prior year period.
• For the three months ended April 30, 2025, the company's net loss was $580,000, compared to $857,000 in the same period last year.
• Total revenue for the nine months ended April 30, 2025, was $1,438,000, a slight decrease from $1,489,000 in the prior year.
• Net product sales for the three months ended April 30, 2025, increased to $489,000 from $440,000 in the comparable prior year period, driven by increased sales across its distribution network.
• The company's gross margin percentage decreased slightly to 57% for the three months and 58% for the nine months ended April 30, 2025, primarily due to increased sales of lower margin packaging configurations.
• Selling, general and administrative expenses decreased significantly by $608,000 to $2,528,000 for the nine months ended April 30, 2025, mainly due to reduced personnel costs, professional service fees, and board of director fees.
• As of April 30, 2025, the company had a cash balance of $540,000 and a stockholders' deficiency of $4,814,000.
• The company used $1,559,000 in operating activities during the nine months ended April 30, 2025.
• Convertible notes payable to related parties increased substantially to $4,899,000 as of April 30, 2025, from $2,949,000 at July 31, 2024, with $1,750,000 in new proceeds from these notes during the nine-month period.
• The company received $82,000 from the U.S. Government's Employee Retention Tax Credit Program during the nine months ended April 30, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, negative cash flow from operations, and a growing stockholders' deficiency, leading to substantial doubt about its going concern ability. While there are some positive signs like reduced operating expenses and increased quarterly sales, the heavy reliance on related-party debt and the explicit going concern warning indicate a precarious financial position.

Positives

• Net loss improved for both the three-month ($580,000 vs $857,000) and nine-month ($2,067,000 vs $2,594,000) periods ended April 30, 2025, compared to the prior year.
• Net product sales increased by $49,000 to $489,000 for the three months ended April 30, 2025, indicating growth in the recent quarter.
• Selling, general and administrative expenses decreased significantly by $608,000 for the nine months ended April 30, 2025, reflecting cost management efforts.
• Net cash used in operating activities decreased to $1,559,000 for the nine months ended April 30, 2025, from $1,938,000 in the prior year, indicating improved operational cash burn.
• The company received $82,000 from the U.S. Government's Employee Retention Tax Credit Program, contributing to other income.

Negatives

• The company has a history of recurring losses and a stockholders' deficiency of $4,814,000 as of April 30, 2025.
• Total revenue for the nine months ended April 30, 2025, decreased slightly to $1,438,000 from $1,489,000 in the prior year.
• Gross margin percentage decreased slightly due to increased sales of lower margin packaging configurations.
• Interest expense increased significantly by $107,000 to $210,000 for the nine months ended April 30, 2025, primarily due to accrued interest on convertible notes.
• The company continues to rely heavily on debt financing from related parties to fund operations, with convertible notes payable increasing by $1,950,000 during the nine-month period.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operating activities.
• Existing cash resources are not sufficient to meet anticipated needs over the next twelve months, requiring additional capital.
• Uncertainty regarding the availability of additional financing on favorable terms, or at all.
• Potential for substantial dilution to existing stockholders if additional funds are raised through equity issuance.
• Debt financing terms may involve significant cash payment obligations, covenants, and financial ratios that restrict business operations.
• Potential requirement to relinquish rights to products or technology if contracts or license arrangements are entered into for fundraising.
• Risk of delays or scaling back marketing, distribution, and commercialization activities, or cessation of operations, due to insufficient funds.
• Fluctuations in operating results due to unpredictable buying patterns, product mix, component costs, inability to meet demand, timing of R&D and regulatory milestones, unforeseen expense changes, and manufacturing/supply issues.
• Dependence on the acceptance of and demand for its products.
• Reliance on the success of its partners in selling products and obtaining regulatory approvals.
• Costs associated with further developing existing products and technologies, and investing in new product/technology development.
• Costs to attract and retain personnel with required skills.
• Costs to file, prosecute, and defend intellectual property rights.

Future Outlook

The company's future capital requirements depend on factors such as product acceptance and demand, success in sales and regulatory approvals, costs of product development, and business growth. It anticipates needing to continue funding operations through equity and debt securities until positive cash flow is consistently generated. There is no assurance that additional financing will be available on favorable terms, and equity issuance would likely result in substantial dilution.

Management Comments

• "Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform."
• "We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain."
• "We plan to leverage our technology platform through licensing and distribution collaborations to create new products and explore additional markets, aiming to generate multiple revenue streams."
• "We are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future."

Industry Context

PURE Bioscience operates in the antimicrobial products market, specifically targeting food safety with its patented stabilized ionic silver (SDC) technology. The company's strategy of expanding its distribution network and seeking third-party partnerships for international approvals aligns with common growth strategies in specialized chemical and biotech industries. The focus on non-toxic, broad-spectrum antimicrobial agents addresses a growing demand for safer and more effective hygiene solutions, particularly in the food industry where pathogen control is critical.

Corporate Governance

Related Party Transactions

• Tom Y. Lee, a member of the Board of Directors, invested $500,000 in the 2025 Private Placement on September 16, 2024, and an additional $1,250,000 in subsequent closings under the 2025 Note Purchase Agreement.
• Tom Y. Lee also invested $500,000 in the March 2024 Private Placement and an additional $500,000 in June 2024 under the 2024 Note Purchase Agreement.
• Messrs. Tom Y. Lee and Ivan Chen, both Board members, invested $1,000,000 and $15,000 respectively in the July 2023 Private Placement, with Mr. Lee investing an additional $785,000 in October 2023.
• As of April 30, 2025, accounts payable include $249,000 in board fees due to officers and directors.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future equity raises and potential loss of investment due to going concern doubts. Existing stockholders' deficiency has worsened.
• Employees/Officers/Directors/Consultants: Benefit from share-based compensation plans (stock options, RSUs) but face uncertainty regarding the company's long-term viability.
• Customers: Continued product availability and support depend on the company's ability to secure ongoing financing and maintain operations.
• Creditors (especially related parties): Have provided substantial financing through convertible notes, indicating a high level of exposure and reliance on the company's future performance and ability to convert debt to equity or repay.
• Suppliers: Increased accounts payable to contract manufacturers suggest growing obligations, potentially impacting supplier relationships if not managed effectively.

Next Steps

• Continue to grow and support the distribution network for SDC-based products.
• Seek and establish partnerships with third parties for international market approvals of SDC-based products.
• Develop additional proprietary products and applications leveraging the SDC technology platform.
• Protect and enhance intellectual property rights related to SDC technology.
• Secure additional financing through equity or debt securities to fund operations until positive cash flow is achieved.

Key Dates

Recommendation

Keywords

Antimicrobial products, Silver Dihydrogen Citrate (SDC), Food safety, Disinfectant, Sanitizer, Food processing aid, Biotechnology, Specialty chemicals, SEC filing, 10-Q, Quarterly report, Going concern, Convertible notes, Related party transactions, Financial performance, Liquidity, Capital resources